Genelux Corporation Share Price & Technical Analysis
GNLX · $2.92 (0.00%)
Healthcare / Biotechnology
$2.92
0.00%
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a tec…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 4 years shown)
12% return in May, -7% avg return in past 3 year May month.
-25% return in 2026, 63% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -39% | 11% | -17% | 8% | 12% | – | – | – | – | – | – | – | -25% |
| 25 | 67% | 17% | -36% | -7% | -11% | 16% | 17% | 0% | 27% | 93% | -31% | -20% | 132% |
| 24 | -23% | -32% | -14% | -52% | -13% | -29% | 0% | 10% | 14% | 33% | -23% | -11% | -139% |
| 23 | -5% | 157% | 94% | -11% | 4% | 15% | -35% | 20% | 3% | -40% | -21% | 16% | 196% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$128.24M
P/E ratio
—
52W high
$8.54
52W low
$2.29
Volume
75,694
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Genelux Corporation share price today?
- Genelux Corporation (GNLX) last traded around $2.92 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GNLX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GNLX. Download the app for real-time alerts.
- How can I analyze Genelux Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.